RubrYc’s lead programs include RTX-002, an anti-PD-1 agonist for serious autoimmune diseases such as systemic lupus erythematosus and multiple sclerosis, and RTX-003, an anti-CD25 antibody that ...

Scholar Rock has submitted its anti-myostatin antibody apitegromab for FDA approval, just months after reporting that it hit its primary endpoint in phase III for spinal muscular atrophy (SMA).

Antibodies bind to specific antigens on pathogens. This means that only one type of antibody will bind to a matching antigen. For example, an antibody that can recognise an antigen on the ...